Revolution Medicines, Inc. Q2 FY2025 earnings call

• Pipeline progress: Three clinical stage RAS(ON) inhibitors - daraxonrasib, elironrasib, zoldonrasib.
  • Daraxonrasib: Advanced clinical program, received Breakthrough Therapy designation for previously treated metastatic pancreatic cancer with KRAS G12 mutations. RASolute³⁰² Phase III trial enrolling well, expects data readout in 2026. Plans for first-line and adjuvant trials in pancreatic cancer.
  • Elironrasib: Granted Breakthrough Therapy designation for locally advanced or metastatic KRAS G12C NSCLC. Data on combinations with other inhibitors and pembrolizumab.
  • Zoldonrasib: Promising data for previously treated RAS G12D NSCLC. Evaluating combination settings.
  • New clinical collaboration with Summit Therapeutics to evaluate combinations of Summit's ivonescimab with daraxonrasib, elironrasib, and zoldonrasib.
  • Royalty Pharma partnership: Provides $2B in committed funding, including synthetic royalty and corporate debt, for flexible access to capital to fuel development and commercialization plans.

No detailed financial performance by product segment with revenue contribution percentages provided in the transcript.

• Projected full year 2025 GAAP net loss between $1.03 billion and $1.09 billion.
  • RASolute³⁰² Phase III trial expected to complete enrollment in 2025 and data readout in 2026.
  • Financial flexibility from Royalty Pharma partnership to support evolving cash flow, capital needs, and capital formation strategy.

• Actual results may differ materially from forward-looking statements due to various risks and uncertainties.
  • Regulatory uncertainties in trial approvals and timelines for clinical studies.
  • Challenges in clinical trial enrollments and potential delays in data readouts.

Q: Michael Schmidt asks about RASolute 302 study winding down U.S. sites and comments on chemo combinations in front-line PDAC study.

A: Mark and Steve Kelsey comment on enrollment progress, study design considerations, and focus on safety and dose intensity.

Q: Marc Frahm follows on, asking about characterizing chemotherapies in front-line PDAC trial and guidance on data readout for RASolute 302.

A: Mark and Steve Kelsey discuss chemotherapy dosing at national-tolerated dose, focus on dose intensity and safety, and mention first analysis expected in 2026.

Q: Jonathan Chang asks about additional color on daraxonrasib combination data forming front-line PDAC registrational study design.

A: Mark and Steve Kelsey state they are building a data set to guide study design, focusing on safety and dose intensity.

Q: Ellie Merle asks about RAS up-regulation as a resistance mechanism and thoughts on RAS degraders vs. inhibitors.

A: Steve Kelsey discusses RAS amplification as a resistance mechanism and states no evidence degraders are superior to inhibitors based on current literature.

Q: Kelly Shi asks about front-line pancreatic cancer trial design sign-off by regulatory agencies and interim data from second-line trial.

A: Mark states they don't provide blow-by-blow updates on regulatory interactions but are making good progress.

Q: Andrea Newkirk asks about pre-commercial activities for daraxonrasib launch and learnings from Lumakras/Krazati launches.

A: Anthony Mancini discusses launch readiness plans, market-shaping activities, and building operational capabilities.

Q: Jay Olson asks about prioritizing combinations with Summit's ivonescimab and potential of ivonescimab plus daraxonrasib in first-line NSCLC.

A: Mark and Wei Lin discuss combination potential, crosstalk between pathways, and expectation of additive antitumor activity.

Q: Ami Fadia's representative asks about accelerated approval for RASolute 302 data and how RAS(ON) inhibitor plus PD-1 VEGF inhibitor improves efficacy in RAS tumors.

A: Mark and Wei Lin discuss accelerated approval possibilities and crosstalk between pathways enhancing antitumor activity.

Q: Alec Stranahan asks about data points waiting on for zoldonrasib and elironrasib and synergies with Iambic collaboration.

A: Mark discusses ongoing studies and data collection for zoldonrasib and elironrasib, and how Iambic's AI technology can enhance drug discovery by processing large data sets.

Q: Peter Lawson asks about U.S. field team build-out and milestones for PRMT5 combo in tumor types.

A: Anthony Mancini discusses U.S. field team build-out progress, and Steve Kelsey comments on PRMT5 combo focusing mainly on pancreatic cancer with MTAP deletion.